1. Home
  2. NXL

NXL

Nexalin Technology Inc.

Logo Nexalin Technology Inc.

Health Care

Medical Specialities

Nasdaq

as 04-16-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
-
.
-
-
%

Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Founded: 2010 Country:
United States
United States
Employees: N/A City: HOUSTON
Market Cap: 17.0M IPO Year: 2022
Target Price: N/A AVG Volume (30 days): 795.9K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.63 EPS Growth: N/A
52 Week Low/High: $0.25 - $3.40 Next Earning Date: 05-08-2024
Revenue: $110,748 Revenue Growth: -91.62%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: